Further research is required to clarify its role in humans
N., Kwok, W., Lau, M., Wong, A
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Salussolia CL, Klonowska K, Kwiatkowski DJ, Sahin M
This makes it suitable for multi-use access when aseptic technique is followed
Ceramides, which are elevated in both GWS and ME/CFS, are implicated in the activation of pro-inflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor (TNF-) within immune cells such as macrophages, as well as in serum (Germain et al., 2020